Number of events observed in the CHOP and R-CHOP arms after a 10-year median follow-up period
| Type of event . | CHOP . | R-CHOP . |
|---|---|---|
| PD during treatment | 44 (22.3%) | 19 (9.4%) |
| New unplanned treatment | 9 (4.6%) | 11 (5.4%) |
| Progression after stable disease | 1 (0.5%) | 1 (0.5%) |
| PD after partial response | 5 (2.5%) | 6 (3.0%) |
| Relapse for CR patients | 71 (36.0%) | 49 (24.3%) |
| Death without PD during treatment | 12 (6.1%) | 12 (5.9%) |
| Death without PD after treatment | 16 (8.1%) | 33 (16.3%) |
| No event | 39 (19.8%) | 71 (35.1%) |
| Type of event . | CHOP . | R-CHOP . |
|---|---|---|
| PD during treatment | 44 (22.3%) | 19 (9.4%) |
| New unplanned treatment | 9 (4.6%) | 11 (5.4%) |
| Progression after stable disease | 1 (0.5%) | 1 (0.5%) |
| PD after partial response | 5 (2.5%) | 6 (3.0%) |
| Relapse for CR patients | 71 (36.0%) | 49 (24.3%) |
| Death without PD during treatment | 12 (6.1%) | 12 (5.9%) |
| Death without PD after treatment | 16 (8.1%) | 33 (16.3%) |
| No event | 39 (19.8%) | 71 (35.1%) |
CHOP indicates cyclophosphamide, doxorubicin, vincristine and prednisone; R-CHOP, rituximab-CHOP; PD, progressive disease; and CR, complete response.